Papillomavirus Infections Clinical Trial
Official title:
Human Papillomavirus 6/11 in the Lower Airway of Neonates
Vertical transmission of human papillomavirus (HPV) 6/11 leads to infection in the lower airway of neonates. The presence of HPV 6/11 may later cause juvenile onset recurrent respiratory papillomatosis (JORRP).
Juvenile onset recurrent respiratory papillomatosis (JORRP) is caused by human
papillomavirus (HPV), almost exclusively type 6 and 11. The disease is well-known for its
recurrence and difficulty in management. The peak incidence is around 2-3 year of age. Since
HPV infection has always been considered a sexual transmitted disease, the rate of vertical
or perinatal transmission had been studied extensively. However, few studies focused on HPV
6 and 11.
To the best of our knowledge, in the several large-scale studies available for HPV infection
in the newborn, no case of HPV 6/11 infection had been identified. Most of these studies had
specimens taken from the oral cavity of newborn. In contrast to the occurrence of JORRP in
the larynx, trachea and lower respiratory tract, if vertical transmission of HPV 6/11 does
exist, specimens from lower respiratory tract of newborn is mandatory to detect any possible
infection.
There is no study available about HPV 6/11 infection in the lower airway of healthy
neonate/children. In some studies of adults, the prevalence of HPV 6/11 in larynx or vocal
cord of patients without recurrent respiratory papillomatosis ranged between 19~25%. In
contrast, several studies had specimen taken from the non-disease lower airway (trachea,
vocal cord) and/or larynx of patients with JORRP. Except for the almost 100% presence of HPV
6/11 DNA in the diseased site, 38~60% of specimens taken from non-disease site were also
positive for the viral DNA, showing that latent infection is not infrequent in normal
airway, and may later cause active disease by mechanism still unknown to date.
The largest national registry of JORRP to date was conducted in the US and had 603 cases.
The study showed that there was a significant association between younger age at diagnosis
and papillomas occurring below the larynx (mean age 4.6 VS 2.1 years, p=0.009). This finding
further emphasizes the importance of getting specimen at the laryngeal level, especially in
neonates.
The aim of our study is to examine the presence of HPV 6/11 DNA in lower respiratory tract
specimens from newborn. To get the lower respiratory tract specimen without unnecessary
medical intervention, only those needed intubation will be included in this study. Specimens
from bronchial lavage (or scraping?) will be obtained after getting informed consent from
the parents, and undergo PCR to identify the presence of HPV 6/11 DNA.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00973856 -
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
|
N/A | |
Active, not recruiting |
NCT05580341 -
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
|
Phase 3 | |
Completed |
NCT06399341 -
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
|
||
Recruiting |
NCT03548740 -
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
|
||
Completed |
NCT00092547 -
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
|
Phase 3 | |
Completed |
NCT00157950 -
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
|
Phase 3 | |
Recruiting |
NCT00365729 -
Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men
|
N/A | |
Completed |
NCT03584308 -
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
|
Phase 2 | |
Not yet recruiting |
NCT04115787 -
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
|
||
Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
Recruiting |
NCT04694495 -
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
|
||
Completed |
NCT06439433 -
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
|
Phase 2 | |
Completed |
NCT00380367 -
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
|
Phase 3 | |
Completed |
NCT01894425 -
Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation
|
N/A | |
Completed |
NCT00685412 -
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
|
Phase 1 | |
Completed |
NCT00365716 -
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
|
Phase 2 | |
Completed |
NCT04772534 -
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
|
Phase 3 | |
Completed |
NCT05119855 -
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
|
Phase 3 | |
Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 | |
Completed |
NCT02631863 -
Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)
|
Phase 2 |